Recent advances in managing chemotherapy-induced peripheral neuropathy: A systematic review

Wang, Mian; Pei, Ziwen; Molassiotis, Alex

doi:10.1016/j.ejon.2022.102134

Cited by 5 publications

(4 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, other RCTs also demonstrated that acupuncture can alleviate the neuropathic pain (eg, hand numbness, tingling, and pain) of CIPN and increase touch perception thresholds ( 46 , 47 ). In addition, several systematic reviews have been published in 2022 to evaluate the effects of acupuncture therapies on CIPN ( 48 – 50 ). According to the theory of traditional Chinese medicine, the acupoints (eg, Qihai, Neiguan, Hegu, Zusanli, Sanyingjiao) selected to relieved CIPN in cancer patients are characterized by tonifying Qi, regulating Qi and blood circulation, and treating localized symptoms.…”

Section: Discussionmentioning

confidence: 99%

Global research trends of acupuncture therapy on cancer pain: A bibliometric and visualized study

Zhao²,

Zhao³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe number of publications on acupuncture for cancer pain is increasing rapidly with an upward tendency. Considering that no bibliometric articles related to this topic have been published yet. It is necessary to evaluate the global scientific output of research in this field, and shed light on the direction of clinical cancer pain management in the future.MethodsResearch publications regarding acupuncture on cancer pain from inception to 2022 were downloaded from the Web of Science Core Collection. Bibliometric analyses were performed using CiteSpace software, the bibliometrix R package, and VOSviewer software. Network maps were generated to assess the collaborations between different countries, institutions, authors, and keywords. And clusters map was generated to evaluate reference.ResultsA total of 790 articles related to acupuncture therapy for cancer pain were identified. We observe that the number of publications is gradually increasing over time. China and the United States were the main contributors. Mem Sloan Kettering Canc Ctr (38 papers) and Beijing Univ Chinese Med (28 papers) contributed the most publications, becoming the leading contributors in this field. Although J Clin Oncol (28 articles) ranked ninth in terms of publication volume, it was the journal with the most citations and the highest number of IF (50.717) and H-index (494) at the same time. MAO J from Mem Sloan Kettering Canc Ctr was the most prolific author (23 articles). The main hot topics included matters related to acupuncture (239 times), pain (199 times), management (139 times), quality of life (107 times), electroacupuncture (100 times), and breast cancer (82 times).ConclusionOur bibliometric analysis provides a comprehensive overview of the development of acupuncture for cancer pain, enabling relevant authors and research teams to identify the current research status in this field. At the same time, acupuncture for breast cancer (BC) pain, aromatase inhibitor-induced arthralgia (AIA), and chemotherapy-induced peripheral neuropathy (CIPN) may soon become prospective focus.

show abstract

Section: Discussionmentioning

confidence: 99%

Global research trends of acupuncture therapy on cancer pain: A bibliometric and visualized study

Zhao²,

Zhao³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…There have been a number of clinical studies and systematic reviews of the efficacy of acupuncture in people with CIPN 14 25–29. Most studies assessed the efficacy of EA or acupuncture for CIPN in a postchemotherapy setting16 30–34 where patients have well-established and persistent CIPN, usually 3 months or more after completion of chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Electroacupuncture use for treatment of taxane-induced peripheral neuropathy in patients with breast cancer: protocol for a pilot, randomised, blinded, sham-controlled trial (EA for CIPN)

Choi,

Park,

Lacey

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionChemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of neurotoxic chemotherapy. Acute symptoms of CIPN during treatment can lead to dose reduction and cessation. Trials using electroacupuncture (EA) to treat established CIPN postchemotherapy have shown some efficacy. The current trial aims to assess the feasibility and preliminary efficacy of using EA to treat CIPN during chemotherapy.Methods and analysisThe current study is a single-centre, 1:1 randomised, sham-controlled pilot study set in a tertiary cancer hospital in Sydney, Australia, and will recruit 40 adult patients with early breast cancer undergoing adjuvant or neoadjuvant paclitaxel chemotherapy. Patients who develop CIPN within the first 6 weeks of chemotherapy will receive either true EA or sham-EA once a week for 10 weeks. The coprimary endpoints are recruitment and adherence rate, successful blinding of patients and compliance with the follow-up period. Secondary endpoints are mean change of CIPN symptoms from randomisation to end of treatment, sustained change in CIPN symptoms at 8-week and 24-week follow-up postchemotherapy, proportion of subjects attaining completion of 12 weeks of chemotherapy without dose reduction or cessation, change in acupuncture expectancy response pretreatment, during treatment and posttreatment. The primary assessment tool for the secondary endpoints will be a validated patient-reported outcome measure (European Organisation for Research and Treatment of Cancer Quality of Life Chemotherapy-Induced Peripheral Neuropathy) captured weekly from randomisation to week 12 of chemotherapy.Ethics and disseminationThe study protocol (2021/ETH12123) has been approved by the institutional Human Research Ethics Committee at St Vincent’s Hospital Sydney and Chris O’Brien Lifehouse. Informed consent will be obtained prior to starting study-related procedures. The results will be disseminated in peer-reviewed journals and at scientific conferences.Trial registration numberACTRN12622000081718.

show abstract

“…The pain appears with the progression of cancer, and various anticancer drugs induce neuropathy as a side effect 5 . Duloxetine is currently approved as the only pharmacological intervention for chemotherapy‐induced peripheral neuropathy 6–8 . In addition, the combination of duloxetine and opioids is used for severe cancer pain as an effective treatment 9,10 …”

Section: Introductionmentioning

confidence: 99%

“…5 Duloxetine is currently approved as the only pharmacological intervention for chemotherapy-induced peripheral neuropathy. [6][7][8] In addition, the combination of duloxetine and opioids is used for severe cancer pain as an effective treatment. 9,10 Liver cancer is the major leading cause of cancer-related death, and the most common form of primary liver cancer is hepatocellular carcinoma (HCC).…”

Section: Introductionmentioning

confidence: 99%

Upregulation by duloxetine of the transforming growth factor‐α‐induced migration of hepatocellular carcinoma cells via enhancement of the c‐Jun N‐terminal kinase activity

Matsushima‐Nishiwaki

Kamoi

Kozawa

2023

Cell Biochemistry & Function

View full text Add to dashboard Cite

Duloxetine, a selective reuptake inhibitor for serotonin and norepinephrine, is a medication widely used for major depression. Currently, duloxetine is also recommended for pain related to chemotherapy‐induced peripheral neuropathy or cancer. Previously, we showed that transforming growth factor‐α (TGF‐α) induces the migration of human hepatocellular carcinoma (HCC)‐derived HuH7 cells through the activation of c‐Jun N‐terminal kinase (JNK), p38 mitogen‐activated protein kinase (MAPK) and AKT. In the present study, we investigate whether duloxetine affects cell migration and its mechanism. Duloxetine significantly enhanced the TGF‐α‐induced migration of HuH7 cells. Fluvoxamine and sertraline, specific inhibitors of serotonin reuptake, also upregulated the TGF‐α‐induced cell migration. On the contrary, reboxetine, a specific norepinephrine reuptake inhibitor, failed to affect cell migration. Duloxetine significantly amplified the TGF‐α‐stimulated phosphorylation of JNK, but not p38 MAPK and AKT. In addition, fluvoxamine and sertraline, but not reboxetine, enhanced the phosphorylation of JNK. SP600125, a JNK inhibitor, suppressed the enhancement by duloxetine, fluvoxamine, or sertraline of TGF‐α‐induced migration of HuH7 cells. Taken together, our results strongly suggest that duloxetine strengthens the TGF‐α‐induced activation of JNK via inhibition of serotonin reuptake in HCC cells, leading to the enhancement of cell migration.

show abstract

Recent advances in managing chemotherapy-induced peripheral neuropathy: A systematic review

Cited by 5 publications

References 73 publications

Global research trends of acupuncture therapy on cancer pain: A bibliometric and visualized study

Global research trends of acupuncture therapy on cancer pain: A bibliometric and visualized study

Electroacupuncture use for treatment of taxane-induced peripheral neuropathy in patients with breast cancer: protocol for a pilot, randomised, blinded, sham-controlled trial (EA for CIPN)

Upregulation by duloxetine of the transforming growth factor‐α‐induced migration of hepatocellular carcinoma cells via enhancement of the c‐Jun N‐terminal kinase activity

Contact Info

Product

Resources

About